PubMed Health⌕ Search

Biomedical subjects

M Rajtár

Publications and source records attributed to M Rajtár.

17 recordsLinked to original sources
PubMed2000

Blue nodes left behind after vital blue dye-guided axillary sentinel node biopsy in breast cancer patients.

BACKGROUND: Vital dye-guided sentinel node biopsy is affordable in most hospitals, but may be of limited accuracy in identifying all sentinel nodes. Leaving sentinel nodes in the axilla may result in a false nodal staging of breast carcinomas. METHODS: From a series of 112 successful sentinel lymph node biopsies with Patent Blue dye followed by axillary dissection, 10 cases were identified where 1-3 blue nodes were found in the axillary dissection specimens. These 10 cases were compared with those which had all blue nodes identified during surgery. Five of the 10 patients with missed blue nodes also underwent lymphoscintigraphy with 99m-Tc-labeled colloidal human albumin and all of their nodes were subjected to external gamma well counting postoperatively. RESULTS: There were six false-negative sentinel lymph node biopsies overall, but none in patients with missed blue nodes. Patients with primarily unidentified blue nodes had more sentinel nodes and a higher rate of multiple sentinel nodes than the others. CONCLUSION: Blue nodes missed during surgery may be either true sentinel nodes or second echelon nodes labeled by dye overflow. This type of error may occur in <8% of patients and may lead to false-negative sentinel node-based staging in an even smaller proportion of cases (none in this series).

Adult↗
PubMed1996

[Bone mineral content in osteogenesis imperfecta].

Bone mineral content (BMC) in the radius of 23 osteogenesis imperfecta (OI) patients (1-26 yr) was measured with SPA technique. Comparing the values of OI type I. patients with that of type III. patients, the decrease of BMC was more prominent in the latter group, however, the two group hadn't been distinct from each other at p < 0.05 level. Based on the measurements of 39 relatives (mother, father, brother) the method seems not to be helpful in screening of gene-carrying relatives because of the high variability of the phenotype of the disease. Follow-up SPA studies-avoiding the repositioning errors-inform about the therapeutic effect.

Absorptiometry, Photon↗
PubMed1996

Parotid gland ultrasonography as a diagnostic tool in primary Sjögren's syndrome.

The diagnostic value of parotid gland ultrasonography (Acuson 128, 7 MHz transducer) was studied in 62 patients with primary Sjögren's syndrome (SS) and in 69 controls of similar age and sex distribution. Different degrees (mild, evident or gross) of parenchymal inhomogeneity (PIH) were the most important sonographic changes in SS; they occurred in 83.9% of the patients. The sonographic results (the presence or absence of PIH) were in accordance with the parotid sialographic and scintigraphic findings and the histology of the minor salivary glands in 87.3, 84.7 and 84.3% of the cases, respectively. Of the degrees of PIH, only evident and gross PIH are thought to be of true diagnostic value for SS. On the basis of the good agreement between the sonographic and sialographic results, consideration of the introduction of parotid sonography as an alternative to sialography is suggested in SS if the latter method cannot be performed.

Adult↗
PubMed1993

[Measurement of bone mineral content by single-photon absorptiometry in children].

Bone mineral content (BMC) was measured in 64 children (33 boys [aged 4-17] and 31 girls [aged 2-12]) having no signs of metabolic bone disease, at the distal third of their radius using single photon absorptiometry (SPA), to establish normative data. Relationships were studied between the obtained bone mineral content and the age, weight, as well as height of children. The obtained BMC values were compared with that of healthy Swedish and American children. Authors suggest the routine use of SPA in home children suffering from metabolic bone diseases.

Absorptiometry, Photon↗
PubMed1990

[Bone scintigraphy in breast cancer: a ten-year follow up study].

The value of bone scanning in the primary staging and clinical course of breast cancer was studied in a 10-years follow-up. Bone metastases (BM) were detected at the time of primary diagnosis in 6.8% of the patients. After primary therapy, the skeleton was the first site of the relapse in 42% of the cases. During the follow-up, BM were revealed in 25% of 623 patients a mean of 22.3 months after the operation. BM were manifested in 17% of the cases with small primary (pT1) tumors and negative axillae. Forty-three percent of the patients had no symptoms at the time of BM diagnosis. The mean survival after the appearance of BM in 163 patients was 18.2 months. Thirteen patients survived more than 5 years after the diagnosis of BM. The routine use of bone scanning is suggested at the time of primary diagnosis, and then yearly in a minimum 5-years period, independently of the symptoms.

Bone Neoplasms↗
PubMed1990

[Internal mammary lymphoscintigraphy in breast cancer].

Clinical importance of the internal mammary radionuclid lymphoscintigraphy (IM RNLS) have been studied in 203 breast cancer patients at the primer staging in 94 unilateral, 7 bilateral independent breast tumor, 13 inflammatory breast cancer, and in the frame of the clinical follow-up in 41 local/regional recurrence, 9 soliter sternal lesion and 2 metastatic bilateral breast tumor. Based on the results the routine use of the IM RNLS is suggested beyond the primer staging in the course of the clinical follow-up at the appearance of the above mentioned entities related to the lymphogen tumor spread.

Breast Neoplasms↗
PubMed1989

[The role of bone scintigraphy and its value in the staging and follow up of prostatic carcinoma].

The role and value of bone scintigraphy in the staging and follow-up of prostatic cancer. Bone scintigraphy was performed in 100 patients with prostatic cancer at the time of histological diagnosis, and during 6 years follow-up in predefinied manner. The sensitivity of the method was enhanced by the results in the case of early M0-1 staging (the rate of the skeletal metastasis was 41% at the first seen). During the follow-up only 8 further cases of skeletal metastasis was observed. In most of the cases the skeletal metastasis was already disseminated at the first seen, the hot spots were located mainly at the pelvis and spine. In six cases "super bone scan" was observed. The conventional hormone therapy resulted in regression in 7 of the patients with skeletal metastasis. According to the authors' experiences the bone scintigraphy is indispensable at the diagnosis in the correct staging, and useful in the patient's follow-up.

Bone and Bones↗
PubMedDate not supplied

Bone marrow (reticuloendothelial system) scintigraphy for haematological follow-up of radiochemotherapy-treated patients.

To assess the bone marrow capacity before a new treatment decision, 99mTc-human serum albumin bone marrow scintigraphy (with qualitative and quantitative evaluation) was performed in 32 patients with solid tumours or malignant lymphomas previously treated with radiochemotherapy. In the group with a normal bone marrow capacity, the blood counts were normal (14/16 cases) or became normal (2/16 cases) in the follow-up period, and the examined marrow samples exhibited normal haemopoiesis. In the group with a reduced bone marrow capacity, one or more blood counts were low in 14/16 cases. Decreased haemopoiesis was observed in only 4 of 8 examined marrow samples. The following conclusions were drawn. (1) A scintigraphically normal bone marrow capacity relates to normal haematological parameters, and therefore treatment plans could be decided on. (2) Although a reduced bone marrow capacity indicates pathological haematological conditions in the majority of cases, further studies are needed to evaluate its precise significance. (3) Application of this non-invasive, inexpensive, repeatable, non-immunizing method is recommended before a therapeutic plan is decided on for patients at considerable haematological risk.

Adult↗
PubMedDate not supplied

Value of 99m-Tc MIBI and 99m-Tc(V) DMSA scintigraphy in evaluation of breast mass lesions.

Among several investigative methods currently undergoing evaluation for the differentiation of biological features of breast mass lesions, mammoscintigraphy with different radiopharmaceuticals appears promising. This study evaluated the efficacy of 99m-Tc MIBI and 99m-Tc(V) DMSA mammoscintigraphy in the detection of malignant focal breast lesions. Mammography, ultrasonography, 99m-Tc MIBI and 99m-Tc(V) DMSA mammoscintigraphy were performed in 51 women with palpable breast mass lesions. Following surgical removal of the abnormalities, histological examination revealed 40 malignant and 11 benign breast mass lesions. In mammoscintigraphy, early (5 minute p.i. of MIBI, 2 hours p.i. of DMSA) and late (2 hours p.i. of MIBI and 5 hours p.i. of DMSA) planar images of the breast and the axillary regions were evaluated visually and quantitatively. The efficacy of the methods was assessed via ROC curves and variance analysis. The visual scores and the quantitative T/NT values with MIBI demonstrated a significant difference between malignant and benign breast mass lesions. A significant difference was also found as concerns the grade of malignancy from the MIBI accumulation. The late MIBI images seemed optimal. The DMSA values indicated no relationship with the breast lesion malignancy. In the detection of metastatic lymph node involvement the sensitivity and specificity with mammography and ultrasonography were 57% and 85%, with MIBI 53% and 81%, and with DMSA 53% and 95%, respectively. It is concluded that MIBI (2 hours p.i.) mammoscintigraphy is a useful and simple method for differentiation of malignant breast abnormalities from benign lesions and for determination of the grade of malignancy. DMSA mammoscintigraphy appears superior to MIBI only in the detection of axillary lymph node metastases.

Adult↗